Along with its first quarter results, Durham’s Heat Biologics (Nasdaq: HTBX) has outlined a new strategy focusing on combination therapies for the treatment of cancer – specifically, with checkpoint inhibitors or T cell co-stimulators – alone.
The strategy comes at a time when the company has seen positive data from its ongoing Phase 2 trial of HS-110 for the treatment of lung cancer in combination with Bristol-Myers Squibb checkpoint inhibitor nivolumab,according to Heat CEO Jeff Wolf said…
Along with its first quarter results, Durham’s Heat Biologics (Nasdaq: HTBX) has outlined a new strategy focusing on combination therapies for the treatment of cancer – specifically, with checkpoint inhibitors or T cell co-stimulators – alone.
The strategy comes at a time when the company has seen positive data from its ongoing Phase 2 trial of HS-110 for the treatment of lung cancer in combination with Bristol-Myers Squibb checkpoint inhibitor nivolumab,according to Heat CEO Jeff Wolf said…